ArticleBMC infectious diseases2026
Pediatric lung abscesses: a 13-year journey from diagnosis to treatment.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosis, management, and clinical outcomes of childhood invasive aspergillosis.BMC pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung abscess is a relatively rare but potentially serious condition in childhood. It is characterized by a localized collection of pus within the lung parenchyma resulting from infectious necrosis. Although its incidence is low, it presents significant clinical challenges due to the risk of severe complications and the prolonged treatment course. This study aims to evaluate the clinical characteristics of pediatric lung abscesses. We also describe diagnostic methods and treatment approaches to contribute to improved disease management.
methodsThis study included patients aged 1 month to 18 years who were diagnosed with and treated for lung abscess at our center between 2012 and 2025. Data on demographic characteristics, as well as clinical, laboratory, and radiological findings and treatment outcomes, were obtained from patient files and hospital electronic medical records.
resultsA total of 33 pediatric patients with lung abscess were included; the median age was 8 years, and 66.7% were male. The most common symptoms were fever (78.8%), cough (78.8%), and dyspnea (39.4%). The median length of hospital stay was 34 days. Primary lung abscesses accounted for 36.4% of cases, whereas 63.6% were secondary and associated with underlying conditions such as immunodeficiency or bronchiectasis. Most abscesses were uniloculated. The most frequently isolated pathogens were Pseudomonas spp. and Staphylococcus aureus. All patients received antibiotic therapy, with a median treatment duration of 34 days. Invasive procedures were required in 30.3% of patients, most commonly percutaneous abscess drainage. The overall mortality and survival rates were 12.1% and 87.9%, respectively; however, all deaths were attributable to underlying diseases rather than lung abscess–related complications.
conclusionsUnderstanding the clinical spectrum and appropriate management of pediatric lung abscess is essential for reducing morbidity and preventing long-term complications. This study contributes to the current literature by providing an up-to-date overview of the diagnostic and therapeutic approaches used in this rare patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.